SBIR/STTR Research Award

MEASURING c-Abl ACTIVITY IN CML USING A HIGH-AFFINITY NANOSENSOR

Award identifier 616c92f960c3cd9bd875a93c686d6dffed0888e274dd191947ee51017f03ec0eAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$112,283

Program and phase

SBIR · Phase I

Award year

2006

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
N-ABL THERAPEUTICS, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2006-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): The ability to monitor and measure protein kinase activity in tumorigenesis and cancer can be indicative of and critical to the transformation process and therefore represents an attractive diagnostic strategy, with a multi-billion dollar market opportunity. In this proposal, we aim to develop a novel, high affinity fluorescent nanosensor and homogeneous assay system for monitoring the phosphorylation of a bona fide peptide substrate by c-Abl, an important kinase involved in the etiology of chronic myelogenous leukemia (CML), using FRET. The technology deployed during this phase of the proposal will directly translate into the development of a sensitive platform for the diagnosis of CML. In specific aim 1, we will synthesize the high-affinity nanosensor. In specific aim 2, we will develop a sensitive one-step assay using this reagent. Specific aim 3 will elaborate on this and test the effectiveness of the nanosensor in measuring c-Abl activity in CML-positive cell lysates. Given the fact that ~400 disorders such as cancer have been associated with protein kinases, the development of a family of sensitive nanosensors such as the one proposed in this grant application will facilitate the diagnosis of these diseases sensitively and selectively and therefore becomes of paramount importance and will find immense utility in all the various facets of our healthcare, from drug-discovery to patient health and point-of-care diagnostics.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.